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Abstract
Background
Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein associated with aggressive
tumor phenotype and poor prognosis in several forms of cancer. The aim of this study was
to investigate PODXL expression in gastric cancer by use of two different antibodies.
Methods
By tumor-tissue microarrays and immunohistochemistry we evaluated PODXL expression
in tumor specimens from 337 patients who underwent surgery for gastric adenocarcinoma
at Helsinki University Hospital. We used two different antibodies: HPA2110, which is a poly-
clonal antibody and an in-house monoclonal antibody called HES9, to investigate the asso-
ciation of PODXL expression with clinicopathologic variables and patient survival.
Results
PODXL staining was positive by the polyclonal antibody in 153 (57.5%) cases and by the
monoclonal antibody in 212 (76%). Polyclonal antibody expression was associated with
intestinal cancer type (p<0.001). Monoclonal antibody staining was associated with age
over 66 (p = 0.001), with intestinal cancer (p<0.001), and with small tumor size ( 5 cm; p =
0.024). Both antibodies were associated with high S-phase fraction (p = 0.022; p = 0.010),
and high tumor proliferation index (Ki-67; p = 0.003; p = 0.001). PODXL positivity by the
polyclonal antibody indicated reduced gastric-cancer-specific 5-year survival of 24.0%
(95% CI 16.9–31.1), compared to 43.3% (95% CI 33.7–52.9) for patients with PODXL nega-
tivity (p = 0.001). The result remained significant in multivariable analysis (HR = 3.17; 95%
CI 1.37–7.34, p = 0.007).
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Conclusion
In gastric cancer, PODXL expression by the polyclonal antibody HPA2110 is an indepen-
dent marker of poor prognosis.
Introduction
In the last decades, the incidence of gastric cancer has declined, especially in Western countries,
apparently due to the declining incidence ofHelicobacter pylori, to better hygiene, and to less
crowded living. Because gastric cancer has a poor prognosis, it is still globally the second most
common cause of cancer-related death [1]. The 5-year survival rate, despite curative surgery, is
only about 10–30% [2]. The high mortality is mostly due to late diagnosis.
The UICC Tumor Node Metastasis (TNM) classification is by far the most consistent prog-
nostic classification system today. However, even within the same stage group tumors, the
course of disease can vary. Creating methods for more accurate assessment of the neoplasia
aggressiveness would be of value when evaluating the prognosis of individual patients with gas-
tric cancer.
Podocalyxin-like 1 (PODXL) is an anti-adhesive transmembrane glycoprotein belonging to
the CD34 family. It is expressed normally by kidney podocytes [3], haemopoietic progenitor
cells [4], vascular endothelia [5], and breast epithelial cells [6].
The clinical significance of PODXL in cancer progression has been investigated in various
carcinoma types, first as a stem cell marker in testicular cancer [7]. A later finding is that
tumor-cell-specific PODXL expression is associated with a more aggressive phenotype and
adverse outcome in several cancer types, for example, in breast [6], prostate [8], ovarian [9],
colorectal [10–12], urothelial bladder [13], pancreatic [14], and periampullary cancer [15].
The aim of this study was to investigate PODXL expression in gastric cancer to reveal its
possible role in aggressiveness and prognosis. We decided to use two PODXL antibodies recog-
nising different epitopes: a monoclonal in-house HES9 antibody and a commercially available
polyclonal HPA2110 antibody. Recently we learned that these two antibodies are independent
markers of poor prognosis in colorectal cancer [12]. The two antibodies can recognise two
groups of colorectal cancer patients, both of whom have a poor prognosis; combined use of
these antibodies revealed a patient group with even worse prognosis [16].
Materials and Methods
Patients
The study comprised 337 consecutive patients who underwent surgery for histologically veri-
fied gastric adenocarcinoma at the Department of Surgery, Helsinki University Hospital, from
1983 to 1999. Diagnosis and staging according to the UICC classification provided 100 (29.7%)
stage IA-IB, 41 (12.2%) stage II, 96 (28.5%) stage IIIA-IIIB, and 100 (29.7%) stage IV patients.
Lymph-node metastases occurred in 184 (55%) and distant metastases in 93 (28%) cases.
Median age was 66 years (range 30–87), and 163 (48%) were women and 174 (52%) men. Total
or partial gastrectomy with extended (D2-D2+) lymphadenectomy was performed in 34 (10%)
patients, total gastrectomy with D1-lymphadenectomy in 161 (48%), and subtotal gastrectomy
with D1-lymphadenectomy in 142 (42%). In total, 143 (43%) patients were operated on with
curative intent, whereas 176 (52%) underwent palliative surgery. None received neoadjuvant
treatment, but 32 (9%) patients received postoperative adjuvant treatment (28 chemotherapy,
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2 radiotherapy; 2 received both). Survival data and cause of death until November 2013 came
from patient records, the Population Register Centre of Finland, and Statistics Finland.
The study was approved by the Surgical Ethics Committee of Helsinki University Hospital
(Dnro HUS 226/E6/ 06, extension TMK02 §66 17.4.2013) and the National Supervisory
Authority of Welfare and Health gave permission to use the tissue samples without individual
consent in this retrospective study (Valvira Dnro 10041/06.01.03.01/2012).
Tissue samples
Formalin-fixed and paraffin-embedded surgical tissue samples came from the archives of the
Department of Pathology. The patient tissues were de-identified and analyzed anonymously.
Histopathologically representative areas of tumor specimens were defined and marked on hae-
matoxylin- and eosin-stained slides. Three cores from each tumor block were sampled with
0.6-mm punchers and embedded in a new paraffin block by a semi-automatic tissue microar-
rayer (Tissue Arrayer 1, Beecher Instruments Inc., Silver Spring, MD, USA). Of the six tissue-
array blocks prepared, each contained 24–192 tumor samples. Sections of 4 μm each were cut
and processed for immunohistochemistry.
Antibodies
We compared two PODXL antibodies against different epitopes. The polyclonal antibody
(HPA2110, Atlas Antibodies, Stockholm, Sweden) was raised against a peptide with the amino
acid residues 278–415 of PODXL, and the monoclonal in-house antibody HES9 [12] recognises
the amino acid residues 189–192 of PODXL. Both epitopes occur in the extracellular part of
the PODXL molecule. The epitope sequence of the HPA2110 matches three protein coding
PODXL splice variants with 100% (PODXL 001, 005, and 201, The Human Protein Atlas). The
fourth splice variant matches with 87% (PODXL 202). The epitope sequences of the HES9
matches 100% with all splice variants. The antibodies are described in detail [12,17,18].
Immunohistochemistry
Sections were fixed on slides and dried for 12 to 24 hours at 37°C, then were deparaffinized in
xylene and rehydrated through gradually decreasing concentrations of ethanol to distilled
water. For antigen retrieval, sections were treated in a PreTreatment Module (Lab Vision
Corp., Fremont, CA, USA) in Tris-HCl buffer (pH 8.5) for 20 minutes at 98°C. Sections were
stained in an Autostainer 480 (Lab Vision) by the Dako REAL EnVision Detection System,
Peroxidase/DAB+, Rabbit/Mouse (Dako, Glostrup, Denmark). The slides were treated for 5
minutes with 0.3% Dako REAL Peroxidase-Blocking Solution to block endogenous peroxi-
dases. Subsequently, slides were incubated for 1 hour with a polyclonal (dilution
1:250 = 2.5 μg/ml) or monoclonal antibody (dilution 1:500 = 5 μg/ml) at room temperature. As
a positive control for each staining series we used samples from renal tissue.
Scoring of immunoreactivity
HPA2110 and HES9 immunopositivity was graded in all available tumor cores. Cytoplasmic
PODXL and HES9 immunopositivity was scored as 0 to 3 based on intensity of cancer cell
immunoreactivity, and the highest score of the three cores served for further analysis. Negative
immunoreactivity was scored as 0, diffuse weak cytoplasmic positivity as 1, moderately positive
or focally strongly positive intensity as 2, and homogeneously strong intensity as 3. All samples
were scored independently by two researchers (A.L. and J.H.) blinded to clinical status and out-
come data. Specimens with discordant scores were re-evaluated, and the consensus score
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served for further analysis. We were able to process and score HPA2110 staining in 266 and
HES9 staining in 279 samples.
Statistical analysis
Associations between HPA2110 and HES9 positivity and clinicopathologic variables were
assessed by the chi-square test or Fisher’s exact test. Correlations between the two podocalyxin
antibodies were assessed by the Spearman correlation test. Disease-specific survival was calcu-
lated from date of surgery to death from gastric cancer.
Survival curves were constructed according to the Kaplan-Meier method and compared
with the logrank test. For univariable and multivariable survival analysis, the Cox proportional
hazard model had the following covariates entered: age, gender, stage, grade, Lauréns classifica-
tion, tumor size, tumor location, PODXL expression determined by HPA2110 staining and
HES9 staining, DNA ploidy, S-phase fraction, Ki-67 expression, and p53 expression. Stage,
grade, Lauréns classification, tumor size, DNA ploidy, S-phase fraction, and expression of
PODXL, HES9, Ki-67, and p53 were entered as categorical covariates. DNA ploidy and S-
phase fraction had been assessed earlier by flow cytometry, and p53, and Ki-67 tissue expres-
sion by immunohistochemistry [19,20]. A p-value of<0.05 was considered statistically signifi-
cant. All statistical analyses were done with IBM SPSS Statistics version 20.0 for Mac (IBM
Corporation, Armonk, NY, USA).
Results
Immunohistochemistry
Cytoplasmic HPA2110 reactivity, evaluated in 266 cases, was negative in 113 (42.5%), weakly
positive in 120 (45.1%), moderately positive in 29 (10.9%), and strongly positive in 4 (1.5%)
cases. Of the 279 cases successfully stained for cytoplasmic expression by HES9, 67 (24.0%)
were negative, 137 (49.1%) weakly positive, 54 (19.4%) moderately positive, and 21 (7.5%)
strongly positive. In the final analysis, weak to strongly positive HPA2110 and HES9 immuno-
reactivity (scores 1–3) was regarded as positive expression. Representative images of immunos-
tainings are in Fig 1. Both HPA2110 and HES9 stained evenly throughout the cytoplasm, with
nuclear nor cell membranous immunopositivity noticeable. The cytoplasmic expression of
podocalyxin by the two different antibodies HPA2110 and HES9 correlated (rs = 0.455,
p<0,001, Spearman's rank correlation test).
Association of HPA2110 and HES-9 with clinicopathological variables
and biomarkers
The associations of HPA2110 and HES9 with clinicopathological variables and molecular bio-
markers were as follows: positive (scores 1–3) HPA2110 staining was associated with intestinal
cancer type (p<0.001), positive HES9 staining was associated with age over 66 (p = 0.001),
with intestinal cancer (p<0.001), and with small ( 5 cm) tumor size (p = 0.024). Both
HPA2110 and HES9 were associated with high S-phase fraction (SPF, p = 0.022; p = 0.010) and
high proliferation index of the tumor (Ki-67, p = 0.003; p = 0.001) (Tables 1 and 2).
Survival analyses
Positive HPA2110 expression indicated a gastric cancer-specific 5-year survival of 24% (95%
CI 16.9–31.1), compared to patients with negative HPA2110 staining with 5-year survival of
43% (95% CI 33.7–52.9) (p = 0.001 log-rank test) (Fig 2 and Table 3). The gastric cancer-spe-
cific 5-year survival of patients with HES9-positive tumor staining was 30% (95% CI 23.1–
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36.1), and for those with negative staining, 40% (95% CI 27.7–52.1; p = 0.130 log-rank test)
(Fig 2).
In subgroup analysis, HPA2110 was a significant marker of poor prognosis in groups of
younger patients (age under 66 years) (p = 0.006), and for male gender (p = 0.002), diffuse-
type cancer (p = 0.001), and stage I patients (p = 0.048) (Fig 3 and Table 3). In the other sub-
groups studied, HPA2110 did not serve as a prognostic marker.
The HPA2110 expression remained significant in multivariable analysis (HR = 3.17; 95% CI
1.37–7.34; p = 0.007; Table 4). Other independent prognostic factors in multivariable analysis
were stage, grade, and DNA ploidy.
Discussion
We show here that cancer-specific 5-year survival was significantly better for gastric cancer
patients having a PODXL-negative tumor. Actually, among stage 1 patients with PODXL-neg-
ative tumors, only one patient died from cancer. In multivariable analysis, positive PODXL
expression served as an independent marker of poor prognosis. Positive PODXL expression
both by the polyclonal antibody HPA2110 and the monoclonal antibody HES9 was associated
with high SPF by flow cytometry and Ki-67 staining, both being markers of high proliferation
of cancer cells and thus of worse prognosis.
Positive expression of PODXL by both antibodies was associated with intestinal cancer type,
but a PODXL-negative tumor proved not to be a prognostic marker in intestinal cancer. Con-
versely, cancer-specific 5-year survival in the subgroup of diffuse type cancer was significantly
Fig 1. Representative images of HPA2110 and HES9 staining representing gastric cancer tumors with negative (A, E), weak (B, F), moderate (C, G),
and strong (D, H) staining in a varying proportion of tumor cells. Images A-D stained with the polyclonal HPA2110 antibody and E-H with the monoclonal
HES9 antibody. Original magnification 40x.
doi:10.1371/journal.pone.0145079.g001
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worse for patients with a PODXL-positive tumor. Generally, diffuse type cancer has been asso-
ciated with worse prognosis than has the intestinal type [21].
To the best of our knowledge, we are the first to report a prognostic value for PODXL in gas-
tric cancer. This has been evident for several other cancer types, like breast [6], prostate [8],
ovarian [9], colorectal [10–12], urothelial bladder [13], pancreatic [14], and periampullary can-
cer [15]. A study on colorectal cancer show concordance between primary tumors and
Table 1. Association of HPA2110 and HES9 with clinicopathological variables in gastric cancer patients.
HPA2110 HES9
Negative Positive Negative Positive
Clinicopathological
variable n n % n % p-value n n % n % p-value
Age, years
< 66 123 58 47.2 65 52.8 0.153 126 42 33.3 84 66.7 0.001
 66 143 55 38.5 88 61.5 153 25 16.3 128 83.7
Gender
Male 137 52 38.0 85 62.0 0.124 143 30 21.0 113 79.0 0.224
Female 129 61 47.3 68 52.7 136 37 27.2 99 72.8
Stage
IA-IB 62 30 48.4 32 51.6 0.709 67 17 25.4 50 74.6 0.594
II 35 13 37.1 22 62.9 36 8 22.2 28 77.8
IIIA-IIIB 83 34 41.0 49 59.0 87 17 19.5 70 80.5
IV 86 36 41.9 50 58.1 89 25 28.1 64 71.9
pT-classiﬁcation
pT1 38 21 55.3 17 44.7 0.250 39 8 20.5 31 79.5 0.684
pT2 39 17 43.6 22 56.4 43 13 30.2 30 69.8
pT3 136 51 37.5 85 62.5 143 32 22.4 111 77.6
pT4 53 24 45.3 29 54.7 54 14 25.9 40 74.1
pN0 107 48 44.9 59 55.1 0.465 112 28 25.0 84 75.0 0.812
pN1 80 36 45.0 44 55.0 89 19 21.3 70 78.7
pN2 79 29 36.7 50 63.3 77 19 24.7 58 75.3
pM0 185 80 43.2 105 56.8 0.704 195 44 22.6 151 77.4 0.388
pM1 81 33 40.7 48 59.3 84 23 27.4 61 72.6
Laurén classiﬁcation
Intestinal 120 37 30.8 83 69.2 <0.001 120 16 13.3 104 86.7 <0.001
Diffuse 146 76 52.1 70 47.9 159 51 32.1 108 67.9
Grade
1 17 5 29.4 12 70.6 0.579 16 3 18.8 13 81.3 0.454
2 39 11 28.2 28 71.8 40 4 10.0 36 90.0
3 50 17 34.0 33 66.0 53 11 20.8 42 79.2
4 7 4 57.1 3 42.9 7 0 0.0 7 100.0
5 1 0 0.0 1 100.0 1 0 0.0 1 100.0
Tumor size, cm
 5 140 56 40.0 84 60 0.335 145 26 17.9 119 82.1 0.024
> 5 122 56 45.9 66 54.1 129 38 29.5 91 70.5
Abbreviations: HPA2110 = polyclonal antibody, HES9 = monoclonal antibody
doi:10.1371/journal.pone.0145079.t001
PODXL as a Prognostic Marker in Gastric Cancer
PLOS ONE | DOI:10.1371/journal.pone.0145079 December 16, 2015 6 / 12
corresponding lymph node metastases in individual patients, and PODXL expression also
remains unaffected by neoadjuvant radiation therapy. These findings support the clinical utility
of PODXL as a marker of poor prognosis [22]. Here we did not study PODXL expression in
lymph node metastases in gastric cancer, and none of the patients in this cohort received pre-
operative chemotherapy, although it is currently rather routine. These effects of preoperative
chemotherapy on PODXL expression in gastric cancer needs further evaluation.
We used two antibodies recognizing PODXL, a commercially available polyclonal antibody
HPA2110 and an in-house monoclonal antibody HES9 [16]. Immunoexpression by the mono-
clonal antibody HES9 was stronger than by the polyclonal antibody. Both antibodies stained
evenly throughout the cytoplasm, and neither stained nuclei nor cell membrane. The variety in
Table 2. Association of HPA2110 and HES9 with molecular biomarkers in gastric cancer patients.
HPA2110 HES9
Negative Positive Negative Positive
Biomarker
n n % n % p-value n n % n % p-value
SPF 7.6
< 7.6 99 49 49.5 50 50.5 0.022 109 35 32.1 74 67.9 0.010
 7.6 120 41 34.2 79 65.8 125 22 17.6 103 82.4
DNA ploidy
Diploid 171 79 46.2 92 53.8 0.084 186 51 27.4 135 72.6 0.080
Aneuploid 73 25 34.2 48 65.8 71 12 16.9 59 83.1
p53
 20% 178 75 42.1 103 57.9 0.871 186 47 25.3 139 74.7 0.488
> 20% 88 38 43.2 50 56.8 93 20 21.5 73 78.5
Ki-67
< 10% 69 38 55.1 31 44.9 0.003 76 27 35.5 49 64.5 0.001
 10% 155 53 34.2 102 65.8 161 27 16.8 134 83.2
Abbrevations: HPA2110 = polyclonal antibody, HES9 = monoclonal antibody; SPF = S-phase fraction
doi:10.1371/journal.pone.0145079.t002
Fig 2. Gastric-cancer-specific survival according to the Kaplan–Meier method. (A) HPA2110 and (B) HES9 expression and survival in gastric cancer
patients.
doi:10.1371/journal.pone.0145079.g002
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staining intensity and distribution was slighter when using the polyclonal antibody, making the
scoring more difficult. Basically PODXL is a transmembrane molecule, and therefore it was
surprising not to find it on cell membranes in gastric cancer cells by either antibody. The mean-
ing of cytoplasmic, non-membraneous, expression of PODXL, its role and function, need fur-
ther evaluation.
Table 3. Kaplan-Meier analysis for disease-specific survival stratified for subgroups of gastric cancer patients.
5-year cumulative survival (95% CI)
Subgroup All patients HPA2110-negative HPA2110-positive p-value
HPA2110 36.3 (31.0–41.6) 43.3 (33.7–52.9) 24.0 (16.9–31.1) 0.001
Age, years
< 66 44.7 (36.9–52.5) 53.9 (40.8–67.0) 27.8 (16.8–38.8) 0.006
66 27.5 (20.2–34.8) 30.2 (16.7–43.7) 20.7 (11.5–29.9) 0.103
Gender
Male 33.2 (25.8–40.6) 43.9 (29.2–58.6) 16.9 (8.4–25.3) 0.002
Female 39.5 (31.7–47.3) 42.6 (29.7–55.5) 32.9 (21.3–44.5) 0.170
Lauréns classiﬁcation
Intestinal 35.9 (27.5–44.3) 43.5 (26.4–60.6) 27.0 (16.8–37.2) 0.150
Diffuse 36.7 (29.6–43.8) 43.1 (31.3–54.9) 20.6 (10.8–30.4) 0.001
Stage
IA-B 86.1 (79.0–93.2) 96.7 (90.2–1.03) 78.8 (63.7–93.9) 0.048
II 40.0 (24.3–55.7) 41.7 (13.9–69.5) 32.9 (12.5–53.3) 0.526
IIIA-B 13.5 (6.2–20.8) 30.5 (12.5–53.3) 6.5 (0–13.6) 0.005
IV 3.6 (0–7.5) 6.4 (0–15.0) 2.2 (0–6.5) 0.057
pT-classiﬁcation
pT1 87.4 (78.6–96.2) 95.2 (86.2–1.04) 80.2 (60.0–1.00) 0.185
pT2 61.5 (48.7–74.2) 54.1 (28.4–79.8) 55.5 (33.7–77.3) 0.960
pT3 19.4 (12.7–26.1) 31.7 (17.8–45.6) 13.9 (6.0–21.7) 0.010
pT4 2.2 (0–6.1) 8.7 (0–20.3) 0 (0–0) 0.152
pN-classiﬁcation
pN0 67.5 (59.7–75.3) 77.6 (65.3–89.9) 54.5 (41.2–67.8) 0.022
pN+ 9.9 (5.4–14.4) 17.9 (7.9–27.9) 4.6 (0.2–8.9) 0.002
Tumor size, diameter
< 5 cm 55.5 (47.9–63.1) 69.2 (56.7–81.7) 36.6 (25.6–47.6) 0.001
 5 cm 12.5 (6.8–18.2) 17.8 (7.0–28.6) 8.7 (1.6–15.8) 0.006
Ploidity
Diploid 40.1 (33.4–46.8) 48.3 (36.7–59.9) 24.8 (15.6–34.0) 0.001
Aneuploid 14.2 (6.4–22.0) 17.1 (8.3–33.4) 13.6 (3.4–23.8) 0.735
SPF
< 7.6 47.6 (39.0–56.2) 54.2 (39.3–69.1) 33.0 (19.5–46.5) 0.036
 7.6 19.9 (13.0–26.8) 31.7 (17.0–46.5) 12.9 (5.3–20.59 0.012
Ki-67
 10% 32.3 (22.1–42.5) 39.6 (23.5–55.7) 16.1 (2.4–29.8) 0.060
> 10% 29.8 (22.5–37.1) 36.7 (23.0–50.4) 22.1 (13.7–30.5) 0.043
p53
 20% 41.5 (34.8–48.2) 49.8 (37.8–61.8) 28.4 (19.4–37.4) 0.004
> 20% 24.7 (15.9–33.5) 29.4 (13.9–44.9) 14.0 (3.6–24.4) 0.071
Abbreviations: HPA2110 = polyclonal antibody, CI = conﬁdence interval; SPF = S-phase fraction
doi:10.1371/journal.pone.0145079.t003
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These different antibodies we used recognize unequal parts of the PODXL molecule, proba-
bly explaining why their expression in some of the specimens differed and results were not
identical. Kaprio et al. [16], used these same antibodies in colorectal cancer, and found an inter-
esting difference between the staining patterns. The polyclonal antibody positivity was mem-
branous [9,10] but, the monoclonal antibody positivity was evident mainly in the cytoplasm. In
colorectal cancer, strong positivity with both the monoclonal and the polyclonal antibody
revealed a subgroup of patients with even worse survival. We did not find this kind of correla-
tion in gastric cancer samples. Overall, positivity among gastric cancer patients was lower than
in colon cancer patients. In colorectal cancer about 94% of the cases were positive for PODXL
with these two antibodies, whereas in gastric cancer positivity appeared in 76% cases with the
monoclonal antibody and in 58% with the polyclonal antibody. The frequency of PODXL posi-
tivity in gastric cancer was close to that seen in breast and ovarian cancer (40% and 67%) [6,9].
PODXL is a transmembrane glycoprotein. It has been shown that mucins, that are also gly-
coproteins, play a role in epithelial to mesenchymal transition (EMT) [23,24]. The role of
PODXL in cancer is unknown but it can be speculated that also PODXL may have a role in
EMT. EMT may explain why patients with high PODXL expression have poorer survival.
The strength of this study is a large patient cohort with gastric cancer and a long follow-up
with reliable clinical follow-up time and survival data. By the TMA technique, only small areas
of the tumor are evaluated compared to whole-tissue sections. In colorectal cancer, Larsson
et al. [22] found that use of whole sections allowed identification of a larger number of tumors
as PODXL-positive than did TMA analysis. Because PODXL expression is heterogeneous, use
of the TMA technique may lead to underestimation of positive cases. Scoring of both monoclo-
nal-antibody and polyclonal-antibody expression was for some specimens difficult; cases with
only a few cancer cells and those in which the value of the cancer cells was unidentifiable were
thus excluded from analysis. This, in part, explains the high number of excluded cases. On the
other hand, the TMA technique allows analysis of large patient cohorts with a homogeneous
staining method.
In conclusion, PODXL immunostaining serves as an independent marker of poor prognosis
in gastric cancer. This is, to our knowledge, the first report on the prognostic value of PODXL
expression in gastric cancer. Future studies should confirm this association and resolve the
mechanisms by which PODXL affects the development and behavior of gastric cancer.
Fig 3. The expression of HPA2110 in the subgroups of (A) stage I patients, and (B) diffuse-type in gastric cancer.
doi:10.1371/journal.pone.0145079.g003
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Table 4. Cox regression analysis for disease-specific survival of gastric cancer patients.
Univariable survival analysis Multivariable survival analysis
Variable Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age, years
< 66 1.00
 66 1.55 1.17–2.04 0.002
Gender
Male 1.00
Female 0.86 0.66–1.14 0.302
Stage
I 1.00
II 5.50 2.87–10.6 <0.001 1.35 0.22–8.44 0.75
III 11.6 6.60–20.3 <0.001 9.55 2.07–44.0 0.004
IV 27.5 15.6–48.5 <0.001 32.2 6.21–167 <0.001
Grade
1 1.00
2 1.14 0.59–2.22 0.694
3 1.55 0.84–2.85 0.161
4 2.51 1.00–6.33 0.051
Lauréns classiﬁcation
Intestinal 1.00
Diffuse 1.02 0.77–1.35 0.893
Tumor size
 5 cm 1.00
> 5 cm 3.44 2.57–4.60 <0.001
Tumor location
Upper third 1.00
Middle third 0.55 0.37–0.81 0.002
Lower third 0.74 0.51–1.06 0.102
Diffuse 2.01 1.18–3.44 0.010
Stump 1.26 0.46–3.50 0.655
HPA2110
Negative 1.00
Positive 1.69 1.23–2.32 0.001 3.17 1.37–7.34 0.007
HES9
Negative 1.00
Positive 1.32 0.92–1.88 0.131
Abbreviations: HPA2110 = polyclonal antibody, HES9 = monoclonal antibody, CI = conﬁdence interval
doi:10.1371/journal.pone.0145079.t004
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